Compare ACADIA Pharmaceuticals Inc. (ACAD) vs American Well Corp (AMWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs American Well Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.42 (market cap $5.07B), while American Well Corp trades at $12.95 (market cap $220.94M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 22.9× American Well Corp's market cap. Which is the better fit depends on your goals.
| ACAD | AMWL | |
|---|---|---|
Market Cap | $5.07B | $220.94M |
Sector | Health | Health |
52-Week High | $29.41 | $13.58 |
52-Week Low | $20.06 | $3.78 |
Enterprise Value | $4.19B | $27.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
AMWL trades at $13.58, up 0.44% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $52 million, beating estimates, and continues to narrow losses. Recent news includes a key executive joining Amazon's healthcare unit, potentially opening partnership opportunities.
The outlook is cautiously optimistic as AMWL progresses toward cash-flow breakeven, but persistent net losses and negative margins pose risks. Analyst consensus is mixed, with 33% buy ratings, reflecting uncertainty around profitability timelines amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About American Well Corp
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →
